IP Library › Granted Patent US 10,760,054
Granted Patent B2
US 10,760,054 · App. 14/847,982 · Granted Sep 1, 2020

Natural killer cells and methods for enhancing viability, proliferation and cytotoxicity of same following cryopreservation

Inventors: Nickolas Chelyapov (Newport Beach, CA); Rafael Gonzalez (Placentia, CA)
Assignee: RESTEM LLC
C12N5/0646C12N2500/40C12N2501/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,760,054
App. No.
14/847,982
Granted
Sep 1, 2020
Kind
B2
Abstract

The invention provides compositions and methods of culturing Natural Killer Cells that increase viability, proliferation and cytotoxicity following cryopreservation.

Claims (35)

1. A feeder free method of increasing viability, proliferation and cytotoxicity of isolated natural killer (NK) cells following cryopreservation comprising:

a. Isolating peripheral blood mononuclear cells (PBMCs) from blood;

b. Expanding NK cells from said PBMCs in a feeder free system;

c. Cryopreserving said expanded NK cells;

d. Thawing said cryopreserved NK cells;

e. Culturing said thawed NK cells in a feeder free system;

f. Adding a supplement to said feeder free system comprising a CpG oligodeoxyribonucleotide (ODN) identical to SEQ ID NO: 1 immediately after thawing.

2. The method of claim 1 further comprising adding IL-12 at a concentration of 1 ug/ml to said feeder free system immediately after thawing.

3. The method of claim 1 further consisting of adding cytokines to said feeder free system immediately after thawing.

4. The method of claim 2 further comprising adding CpG ODN identical to SEQ ID NO: 1 at a concentration of 3 ug/ml to 24 ug/ml.

5. A feeder free method of increasing viability, proliferation and cytotoxicity of isolated NK cells following cryopreservation comprising:

a. Expanding NK cells from PBMCs in a feeder free system;

b. Cryopreserving said expanded NK cells;

c. Thawing said cryopreserved NK cells;

d. Culturing said thawed NK cells in a feeder free system;

e. Adding a supplement to said feeder free system comprising a CpG ODN identical to SEQ ID NO: 1 after thawing.

6. The method of claim 5 further comprising adding IL-12 at 1 ug/ml to said feeder free system after thawing.

7. The method of claim 5 further consisting of adding cytokines to said feeder free system after thawing.

8. The method of claim 6 further comprising adding CpG ODN identical to SEQ ID NO: 1 at a concentration of 3 ug/ml to 24 ug/ml.

9. A feeder free method of increasing viability, proliferation and cytotoxicity of isolated NK cells following cryopreservation comprising:

a. Cryopreserving NK cells expanded in a feeder free system;

b. Thawing said cryopreserved NK cells;

c. Culturing said thawed NK cells in a feeder free system;

d. Adding a supplement to said feeder free system, immediately after thawing, comprising CpG ODN that functions as a pathogen-associated molecular pattern.

10. The method of claim 9 further comprising adding IL-12 at a concentration of 1 ug/ml to said feeder free system immediately after thawing.

11. The method of claim 9 further consisting of adding cytokines to said feeder free system immediately after thawing.

12. The method of claim 10 further comprising adding CpG ODN that functions as a pathogen-associated molecular pattern at a concentration of 3 ug/ml to 24 ug/ml.

13. A feeder free method of increasing viability, proliferation and cytotoxicity of isolated NK cells following cryopreservation comprising:

a. Cryopreserving NK cells expanded in a feeder free system;

b. Thawing said cryopreserved NK cells;

c. Culturing said thawed NK cells in a feeder free system;

d. Adding a supplement to said feeder free system, after thawing, comprising a CpG ODN that functions as a pathogen-associated molecular pattern.

14. The method of claim 13 further comprising adding IL-12 at a concentration of 1 ug/ml to said feeder free system after thawing.

15. The method of claim 13 further consisting of adding cytokines to said feeder free system after thawing.

16. The method of claim 14 further comprising adding CpG ODN that functions as a pathogen-associated molecular pattern at a concentration of 3 ug/ml to 24 ug/ml.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2023
From: CHELYAPOV, NICKOLAS; GONZALEZ, RAFAEL
To: RESTEM LLC
Reel/Frame 063435/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2018
From: REGENERACION TERAPEUTICA S.A.
To: RESTEM LLC
Reel/Frame 046553/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2018
From: REGENERATION WORLDWIDE COMPANY
To: REGENERACION TERAPEUTICA S.A.
Reel/Frame 045208/0839 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2017
From: DAVINCI BIOSCIENCES LLC
To: REGENERATION WORLDWIDE COMPANY, INC.
Reel/Frame 042466/0181 →
Continuity (2)
Provisional Application 62097535 · Dec 29, 2014
Related Publication 20160186138A1 · Jun 30, 2016